onc brain

About · curated by Nick Boehling, MD · @nb2276

    Early signal

    Nomogram for four or more involved nodes in SLN-positive breast cancer

    ForcN0 invasive breast, 1-3 H&E-positive SLNs, no neoadjuvant therapy

    TL;DRAUC 0.83 in derivation and 0.81 in external validation for predicting ≥4 involved nodes after 1-3 positive SLNs, using 7 pathologic factors.

    Why it mattersRadiation oncology

    The RT question is field design. With a <5% predicted ≥4-node risk as the threshold, 34% of the derivation and 37% of the validation cohort were candidates to drop the SCV/apex field. The source ties adding that field to lymphedema rising from 2% to 8% to approximately 9% to 24%. The case for omission rests on high tangents covering most of levels I-II.

    Monday clinic

    In cN0 pts with 1-3 H&E-positive SLNs and no completion ALND, a low predicted ≥4-node risk informs whether to add an SCV/apex field. It does not extend to post-neoadjuvant pts or keratin-only SLN deposits.

    13 details 2 trials watching
    Design

    Retrospective two-center review (MGH n=248, BWH n=154), N=402. Univariate and multivariate logistic regression, forward stepwise selection. External validation in a separate, previously published community-hospital set of 206 pts.

    Population & inclusion

    Clinically node-negative invasive breast cancer with 1-3 H&E-positive SLNs and completion ALND, defined as ≥6 nodes examined. No neoadjuvant systemic therapy. Mastectomy 46%, breast conservation 53%.

    Endpoints

    Outcome modeled: ≥4 involved axillary nodes (SLN plus non-SLN). Model performance was assessed by AUC, Hosmer-Lemeshow, sensitivity and NPV.

    Results

    Seven independent factors: tumor size, lobular histology, LVSI, ENE, number of positive SLNs, macrometastasis, and number of negative SLNs. AUC 0.83 in derivation, 0.81 in validation. At a 5% cutoff, NPV 94.7% and sensitivity 97.5%.

    Radiotherapy

    The authors' hypothesis is that pts below 5% predicted risk could be treated with modified high tangents instead of comprehensive nodal RT to the SCV fossa and axillary apex. That would have spared 34% (derivation) and 37% (validation).

    vs leading data

    Similar in aim to the MD Anderson mastectomy series, where pts without three risk features had <2% risk of ≥4 nodes, and to Chagpar et al's 1,133-pt model. This model adds LVSI and SLN metastasis size. It predates the Z0011 and AMAROS axillary-management era.

    Applies to
    cN0, H&E SLN-positive pts with 1-3 positive SLNs and no neoadjuvant therapy
    Does not represent post-neoadjuvant pts, keratin-only SLN deposits, or pts with ≥4 positive SLNs.
    Limitations

    The ≥6-node ALND definition may include axillary samplings. The abstract and results disagree on the count of ≥4-node pts (87 vs 81). Validation underestimated observed cases, and the validation set was chosen for availability.

    Discussion

    The tool estimates nodal burden, a surrogate for the risk of regional failure. Whether tangent-only RT is safe in the low-risk group needs outcome data the paper doesn't have.

    Rationale

    Retrospective model built on dissected pts with one small external validation. It predicts nodal burden, not regional recurrence after RT field reduction; the omission hypothesis was never tested.

    Open questions
    📚 Sources · 📄 1 paper
    📄 PAPER Katz, Angela; Smith, Barbara L.; Golshan, Mehra et al. · Journal of Clinical Oncology (2008-05)
    Nomogram for the Prediction of Having Four or More Involved Nodes for Sentinel Lymph Node–Positive Breast Cancer
    doi
    Abstract
    Purpose The standard of care for patients with a positive (+) sentinel lymph node (SLN) is axillary dissection; however, for various reasons, some SLN+ patients do not undergo dissection. The purpose of this study was to define possible predictors of having four or more involved nodes to provide information for clinicians and patients making decisions about adjuvant chemotherapy and radiation. Patients and Methods We reviewed the records of 402 patients with invasive breast cancer and one to three involved SLNs who underwent completion axillary dissection at two academic cancer centers. None of these patients received neoadjuvant chemotherapy. Factors associated with having four or more involved axillary nodes (SLNs and non-SLNs) were evaluated by univariate and multivariate logistic regression analysis. Results Eighty-seven patients had four or more positive nodes. On multivariate analysis, having four or more SLNs was associated with tumor histology, primary tumor size, lymphovascular space invasion, extranodal extension, the number of involved SLNs, the number of uninvolved SLNs, and the size of the largest SLN metastasis. A nomogram to predict the probability of having four or more nodes based on patients’ pathologic data was developed from the multivariate logistic regression model. A separate previously published data set of 206 SLN+ patients treated at a community hospital in another city was used to validate this model. Conclusion Patients with a low probability of having four or more nodes can be identified from known pathologic features. The nomogram developed will be helpful to clinicians making adjuvant treatment recommendations.

    Curative Retrospective Early signal

    The longer read

    This paper belongs to the period when sentinel node biopsy had removed the routine axillary dissection but not the uncertainty it used to settle. The clinical question it answers is narrow: if a woman with one to three positive sentinel nodes does not go on to completion dissection, how likely is it that four or more nodes are involved? That threshold mattered because nodal count drove the decision to treat the supraclavicular fossa and axillary apex. The authors frame the nomogram as a way out of a default many radiation oncologists had settled into: comprehensive nodal RT for every SLN-positive pt, which treats the axilla as if it had never been evaluated.

    The model's discrimination is respectable. It held up in a community-hospital set, which is the most useful thing about the validation. But a tool built to predict nodal count is two steps away from the outcome a radiation oncologist actually cares about. The first step is from predicted nodal burden to regional recurrence risk. The second is from recurrence risk to the safety of a reduced field. The paper offers no recurrence data for either. The argument for omitting the third field leans on older reports that supraclavicular failure is rare below four nodes, and the authors themselves concede those reports may undercount failures in that region.

    The methodology should temper confidence in three specific ways. Derivation drew only on pts who underwent dissection, so the people the tool is meant for (those who skip dissection) were excluded by design. The ≥6-node cutoff for a real dissection is a pragmatic proxy that could let samplings in. And the abstract and results disagree on how many pts had four or more nodes, while the reported sensitivity and NPV do not line up neatly with the counts given beside them. None of this sinks the model, but it argues for treating the 5% threshold as an approximate cut point rather than a calibrated one, especially since the nomogram underpredicted in the validation set.

    The practice context has since shifted. Z0011 and AMAROS reframed axillary management for low-volume SLN disease, and MA.20 and EORTC 22922 reopened the case for regional nodal irradiation in node-positive disease more broadly. A tool that helps de-escalate nodal fields sits awkwardly next to trials that pushed toward treating them. Its lasting value is as one input to individualizing the upper-axilla and supraclavicular field when dissection is omitted, not as a stand-alone license to omit. The decision it informs is field extent. It does not address whether nodal RT is indicated at all, which depends on factors beyond nodal count that the model does not capture.